Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...

Add Yahoo as a preferred source to see more of our stories on Google. Ian L. Haddock founder of the normal anomaly I was born in Galveston County, Texas, the very place where, on June 19, 1865, ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

ViiV expects injectables to steal significant market share from oral treatments, such as Gilead’s Biktarvy, which currently dominate the HIV field. In the prevention arena, the company is awaiting an ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...

Please provide your email address to receive an email when new articles are posted on . Among nearly 2,500 women, almost 80% chose long-acting, injectable cabotegravir for HIV PrEP. Reasons included ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...

In a move to increase access to HIV-prevention treatment, the U.S. Food and Drug Administration on Monday approved the use of Apretude – the first injectable pre-exposure prophylaxis treatment aimed ...